We are live on ! Find out more
EBACU

European Biotech Acquisition Corp. Units

Delisted

EBACU was delisted on the 2nd of March, 2023.

30 hedge funds and large institutions have $31.6M invested in European Biotech Acquisition Corp. Units in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

19% less funds holding

Funds holding: 3730 (-7)

23% less capital invested

Capital invested by funds: $41.2M → $31.6M (-$9.63M)

88% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 8

Holders
30
Holders Change
-7
Holders Change %
-18.92%
% of All Funds
0.53%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
4
Reduced
4
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
26
UBS Group
Switzerland
$9K +$8.73K +879 New
PMAM
27
Picton Mahoney Asset Management
Ontario, Canada
$1K
Walleye Capital
28
Walleye Capital
New York
$747
Macquarie Group
29
Macquarie Group
Australia
-$3.78M -378,000 Closed
ACA
30
Arena Capital Advisors
California
-$2.26M -225,899 Closed
BCM
31
BlueCrest Capital Management
Jersey
-$2M -200,000 Closed
CCM
32
CAAS Capital Management
New York
-$999K -100,000 Closed
GF
33
Gabelli Funds
New York
-$733K -73,303 Closed
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
-$686K -68,721 Closed
GCIA
35
Gabelli & Co Investment Advisers
New York
-$657K -65,689 Closed
WAM
36
Wolverine Asset Management
Illinois
-$39K -3,933 Closed

EBACU Hedge Fund Activity: Q3 2021 in Review

30 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Units (EBACU) for Q3 2021, worth a combined $31.6M — down 23% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of EBACU and 1 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was Sage Mountain Advisors, adding an estimated $740K. The largest seller was Macquarie Group, exiting entirely with an estimated $3.78M sold.

  • 30 institutional investors held European Biotech Acquisition Corp. Units (EBACU) as of Q3 2021, down from 37 in Q2 2021.
  • Funds reported $31.6M of European Biotech Acquisition Corp. Units stock for Q3 2021, down 23% quarter-over-quarter.
  • 1 fund opened new European Biotech Acquisition Corp. Units positions in Q3 2021 and 8 closed out, a net change of -7 holders.
  • The largest European Biotech Acquisition Corp. Units buyer in Q3 2021 was Sage Mountain Advisors, an estimated $740K added.
  • The largest European Biotech Acquisition Corp. Units seller in Q3 2021 was Macquarie Group, an estimated $3.78M sold.

Based on aggregated 13F filings for Q3 2021.